Close Menu

lawsuit

Alnylam charged Tekmira with wrongly using trade secrets to bolster its own drug delivery technology-development efforts and to file a patent application on Alnylam's phase I liver cancer drug.

According to Tekmira, AlCana is an “instrument of Alnylam” used to “escape the licensing and royalty obligations” of the companies' agreements.

The high court has ruled in favor of Roche, saying that just because university-based research may been funded by federal dollars it does not override more than 200 years of patent law and take away the rights to a patent from its inventor.

A Marina official confirmed that neither company paid compensation to the other under the terms of the settlement.

Celera and other defendants have entered into a memorandum of understanding in putative class action lawsuits stemming from the company's proposed acquisition by Quest Diagnostics.

Genetic Technologies said it has secured A$14.5 million ($15.2 million) in licensing revenues since it filed its lawsuit in February 2010.

Genetic Technologies granted a non-exclusive license to Orchid Cellmark for a number of patents covering non-coding analysis, gene mapping, and internal standards.

Alnylam charged that Tekmira has itself violated the companies' agreements by filing the suit, which it said ignores “confidential and non-public alternative dispute resolution procedures required under the … agreements."

Brenda Bass “conceived the inventions of all the issued claims of Tuschl-II and at least some pending claims of Tuschl-I well before any date asserted by the currently named inventors,” the University of Utah alleges.

The New Orleans Employees Retirement System alleges Celera and its board undervalued the company in its $671 million sale to Quest.

Pages

23andMe has launched a new tool that estimates someone's risk of developing severe COVID-19 if infected, Bloomberg reports.

The Guardian reports that Pasteur Institute researchers are halting their development of a SARS-CoV-2 vaccine following disappointing initial results.

The Wall Street Journal reports that an increased number of younger patients have been hospitalized as the new SARS-CoV-2 strain spread across the UK.

In Cell this week: proteomic patterns among COVID-19 affected tissue samples, transcriptome atlas of developing intestines, and more.